Basic Tizanidine Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In United Kingdom: Glucophage, Bolamyn, Sukkarto (UK/Ireland)
• ATC Code: A10BA02
• Forms & Dosages: Tablets 500mg/850mg/1000mg (immediate and extended release); oral solution typically 500mg/5mL; modified‑release 500mg/750mg/1000mg
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: EMA/EU authorisations noted; UK‑specific registration details not specified
• OTC / Rx Classification: Prescription‑only medicine (Rx) in most regions

Latest Research Highlights

Patients and clinicians want to know whether tizanidine really reduces spasticity and at what cost in side effects.

Recent UK and EU systematic reviews and randomised trials (2022–mid‑2024) report modest short‑term reductions in muscle tone and spasm frequency versus placebo, with variable benefits for function and mobility.

Head‑to‑head trials show similar efficacy to baclofen in some populations but a higher incidence of sedation and hypotension in tizanidine groups.

Comparisons with benzodiazepines and gabapentinoids show mixed results for pain and spasm control, with differing adverse‑effect profiles influencing choice.

MHRA and EU pharmacovigilance data indicate signals for sedation, dizziness, raised hepatic enzymes and clinically important interactions, especially with CYP1A2 inhibitors such as ciprofloxacin and fluvoxamine.

Ongoing NHS Trust cohort studies in MS and spinal‑injury services are refining long‑term tolerability and fall‑risk data and support shared‑decision approaches in clinic audits.

Clinical Effectiveness In The UK

What do NHS audits and patients report about real use of tizanidine?

Within NHS neurology and rehabilitation services tizanidine is used for focal and generalised spasticity where oral therapy is appropriate.

Audits commonly show symptomatic improvement in muscle tone, reduced spasm frequency and fewer nocturnal cramps for a subset of patients.

Patient‑reported experience highlights faster spasm relief but frequent daytime sleepiness and dizziness that can limit functional gain.

Effectiveness is maximised when tizanidine is combined with physiotherapy, stretching programmes and orthoses under multidisciplinary review.

• Outcome Measures: Modified Ashworth Scale, spasm diaries, Timed Up And Go (TUG), patient‑reported sleep quality.
• Review Schedule: early review at 1–2 weeks for tolerability, then approximately every 3 months in secondary care.

Indications And Expanded Uses

Patients want to know when tizanidine is prescribed and when clinicians use it off‑label.

1. Approved Indications: Symptomatic management of spasticity after spinal cord injury, in multiple sclerosis and adult cerebral palsy (central spasticity).
2. Short‑Term Specialist Use: Acute focal spasm control post‑operatively or for painful muscle spasm when other options are unsuitable.
3. Off‑Label Uses: Chronic myofascial pain, tension‑type headache and adjunctive treatment in complex regional pain syndromes in some private or multidisciplinary clinics, with limited evidence.

Checklist For Documenting Off‑Label Prescribing:

• Clinical rationale recorded in notes and discharge/clinic letters.
• Informed consent discussed and documented.
• Planned review and monitoring schedule agreed.

In pregnancy and breastfeeding data are sparse and specialist obstetric advice is usually sought before prescribing.

Composition And Brand Landscape

What is in the tablet and which brands are commonly seen in the UK?

Active Ingredient: tizanidine hydrochloride (INN: tizanidine hydrochloride).

Typical strengths in UK practice are 2 mg and 4 mg tablets, supplied in branded generics and generics.

Note: the Basic Info block above draws on metformin product packaging as an example of how brand/packaging details are presented; metformin data should not be equated with tizanidine.

Hospital‑only stock routes and NHS trust contracts can determine which brand a pharmacy dispenses, and generic substitution is common where formulary status permits.

Pharmacoeconomics: tizanidine is available as a generic and tends to be low cost compared with some specialist alternatives, though local contracts influence choice.

Contraindications And Special Precautions

Who should avoid tizanidine and what must clinicians watch for?

Absolute contraindication: known hypersensitivity to tizanidine.

Special precautions include significant hepatic impairment, severe hypotension or bradycardia, and co‑prescribing with potent CYP1A2 inhibitors.

Elderly patients are at higher risk of sedation, orthostatic hypotension and falls; start low and titrate slowly with frequent review.

In pregnancy and breastfeeding, many clinicians avoid routine use and seek specialist advice because data are limited.

Lifestyle Restrictions: avoid alcohol and other CNS depressants, and warn about driving or operating machinery until individual effects are known.

Checklist Of High‑Risk Groups:

• Severe hepatic impairment — avoid or monitor LFTs closely.
• Concurrent ciprofloxacin/fluvoxamine — contraindicated or requires major dose change.
• Older adults with fall risk — consider physiotherapy and home safety review.

MHRA Yellow Card interaction alerts frequently reference ciprofloxacin and highlight interaction‑related adverse events in community settings; clinicians routinely flag these in discharge letters.

Dosage Guidelines

How should dosing be started and adjusted in NHS practice?

1. Typical Initiation: 2 mg at night, then increase by 2 mg every 3–7 days according to response and tolerability.
2. Maintenance: commonly 6–18 mg per day divided, for example 2–4 mg every 6–8 hours.
3. Maximum: many clinicians avoid exceeding 36 mg/day; local formularies may set conservative limits.

Titration And Special Populations:

When co‑prescribing CYP1A2 inhibitors substantially reduce dose or avoid the combination.

For discontinuation, taper over several days to reduce rebound hypertension or increased spasticity.

Interactions Overview

Which medicines and habits can make tizanidine dangerous?

Severe interactions centre on CYP1A2 inhibitors such as ciprofloxacin and fluvoxamine, which markedly increase tizanidine levels and risk profound hypotension and sedation.

Other CYP inhibitors and some antidepressants may also raise exposure and require dose changes or alternatives.

Concomitant antihypertensives and central depressants (opioids, benzodiazepines, gabapentinoids) potentiate hypotension and sedation.

Alcohol markedly increases CNS depression and should be avoided while on tizanidine.

MHRA Yellow Card reports commonly cite antibiotics and fall‑related events in older adults; always check medicines reconciliation before starting or issuing antibiotics.

Cultural Perceptions And Patient Habits In The UK

What do UK patients typically ask about when collecting tizanidine?

Many patients expect clear counselling and printed information at the pharmacy about timing, side effects and driving implications.

Online patient forums and NHS Trust feedback show practical advice: start at a low dose, prefer night dosing, and pair medication with physiotherapy.

Community pharmacists are a trusted source and are often asked to run medication reviews and titration checks, sometimes via the NHS App or telephone consultations.

Common Patient Concerns:

• Will it make me sleepy and affect driving?
• Which antibiotics should I avoid?
• How quickly will spasms improve?
• Do I need liver or blood pressure monitoring?

Pharmacist Counselling Checklist:

• Name and purpose of the medicine and dosing plan.
• Interactions to avoid (explicitly name ciprofloxacin/fluvoxamine).
• Driving and alcohol advice; arrange early follow‑up for titration checks.

Availability And Pricing Patterns

How do patients in different UK nations access and pay for tizanidine?

Tizanidine is prescription‑only in the UK and dispensed via NHS or private prescriptions.

In England a standard NHS prescription charge applies per item unless the patient is exempt.

In Scotland, Wales and Northern Ireland most NHS prescriptions are free of charge, but local rules should be checked.

Major pharmacy chains and independents commonly stock generic tizanidine and hospital pharmacies supply trust packs.

Online pharmacies and e‑prescribing have increased access, and in our online pharmacy tizanidine is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Comparable Medicines And Prescribing Preferences

Which alternatives do clinicians consider before choosing tizanidine?

Common comparators are baclofen, diazepam, dantrolene, intrathecal baclofen and botulinum toxin for focal spasticity.

Baclofen is often first‑line for spinal spasticity; tizanidine may be preferred if intermittent dosing or a different adverse‑effect profile suits the patient.

Diazepam provides anxiolysis and muscle relaxation but carries dependence risk.

Dantrolene requires hepatic monitoring and is less commonly used for central spasticity.

Botulinum toxin or intrathecal pumps are options for focal or refractory cases and are arranged via specialist services.

• Baclofen — Pros: established efficacy for spinal spasticity. Cons: dose‑related weakness, sedation in some patients.
• Tizanidine — Pros: intermittent dosing useful for night spasms. Cons: sedation, hypotension, hepatic precautions.
• Diazepam — Pros: rapid relief. Cons: dependence, daytime sedation.
• Botulinum Toxin — Pros: focal, targeted treatment. Cons: specialist delivery and cost.

Referral Flowchart For Primary Care:

1. Identify problematic spasticity limiting function → trial conservative measures (physio, stretching).
2. If oral therapy needed and unclear agent choice → refer to neurology/rehab for tailored plan.
3. Consider botulinum toxin or intrathecal options for focal or refractory spasticity.

FAQ

Will tizanidine make me too sleepy to drive?

It can cause sleepiness and dizziness, so avoid driving until you know how it affects you and follow DVLA guidance; report persistent impairment to your GP.

Can I take antibiotics while on tizanidine?

Avoid ciprofloxacin and fluvoxamine as these interact dangerously; always tell any prescriber or pharmacist that you take tizanidine before antibiotics are issued.

How quickly does it work and how long are reviews?

Some patients notice benefit within days; clinics and GPs usually review tolerability at 1–2 weeks and adjust doses every 2–12 weeks depending on response.

How do I stop it safely?

Taper rather than stop abruptly to reduce risk of rebound spasm or blood pressure changes; follow clinician instructions.

For urgent advice contact NHS 111, your local pharmacy or condition‑specific charities such as the MS Society.

Guidelines For Proper Use

What should pharmacists cover at supply and how do clinics monitor patients?

Counselling Points For Pharmacists:

• Explain indication and expected benefits, dosing schedule and titration plan.
• Name major interactions (explicitly ciprofloxacin and fluvoxamine) and advise avoidance of alcohol.
• Advise on driving and work precautions and when to seek urgent care (syncope, severe sedation, hepatic symptoms).

Document counselling in the patient medication record and communicate via NHS electronic prescription and GP records.

Baseline Monitoring Checklist For Clinics:

• Blood pressure and heart rate.
• Baseline liver function tests (LFTs).
• Medication reconciliation for CYP1A2 inhibitors and CNS depressants.

Red‑Flag Symptoms Requiring Urgent Review:

1. New severe drowsiness or difficulty breathing.
2. Syncope or unexplained falls.
3. Jaundice, persistent nausea or dark urine (possible hepatic injury).

Delivery Across United Kingdom